The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

The oncolytic virus Delta-24-RGD is in clinical trial for adult glioma. Here, the authors show that this virus elicits an immune response in mouse models of pediatric high-grade glioma and diffuse pontine intrinsic glioma, resulting in improved survival.

Guardado en:
Detalles Bibliográficos
Autores principales: Naiara Martínez-Vélez, Marc Garcia-Moure, Miguel Marigil, Marisol González-Huarriz, Montse Puigdelloses, Jaime Gallego Pérez-Larraya, Marta Zalacaín, Lucía Marrodán, Maider Varela-Guruceaga, Virginia Laspidea, Jose Javier Aristu, Luis Isaac Ramos, Sonia Tejada-Solís, Ricardo Díez-Valle, Chris Jones, Alan Mackay, Jose A. Martínez-Climent, Maria Jose García-Barchino, Eric Raabe, Michelle Monje, Oren J. Becher, Marie Pierre Junier, Elias A. El-Habr, Herve Chneiweiss, Guillermo Aldave, Hong Jiang, Juan Fueyo, Ana Patiño-García, Candelaria Gomez-Manzano, Marta M. Alonso
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/e70b68b3d2c14bafb5f5185c1fba26c6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The oncolytic virus Delta-24-RGD is in clinical trial for adult glioma. Here, the authors show that this virus elicits an immune response in mouse models of pediatric high-grade glioma and diffuse pontine intrinsic glioma, resulting in improved survival.

Ejemplares similares